4.8 Article

The SS18-SSX Fusion Oncoprotein Hijacks BAF Complex Targeting and Function to Drive Synovial Sarcoma

Journal

CANCER CELL
Volume 33, Issue 6, Pages 1128-+

Publisher

CELL PRESS
DOI: 10.1016/j.ccell.2018.05.002

Keywords

-

Funding

  1. NIH [1DP2CA195762-01, 5 T32 GM095450-04]
  2. American Cancer Society [RSG-14-051-01-DMC]
  3. Pew-Stewart Scholars in Cancer Research Grant
  4. Alex's Lemonade Stand Foundation Young Investigator Award
  5. Harvard University Graduate School of Arts and Sciences (GSAS) Fellowship
  6. NATIONAL CANCER INSTITUTE [ZIABC011002, ZIABC011734] Funding Source: NIH RePORTER
  7. NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM095450] Funding Source: NIH RePORTER

Ask authors/readers for more resources

Synovial sarcoma (SS) is defined by the hallmark SS18-SSX fusion oncoprotein, which renders BAF complexes aberrant in two manners: gain of SSX to the SS18 subunit and concomitant loss of BAF47 subunit assembly. Here we demonstrate that SS18-SSX globally hijacks BAF complexes on chromatin to activate an SS transcriptional signature that we define using primary tumors and cell lines. Specifically, SS18-SSX retargets BAF complexes from enhancers to broad polycomb domains to oppose PRC2-mediated repression and activate bivalent genes. Upon suppression of SS18-SSX, reassembly of BAF47 restores enhancer activation, but is not required for proliferative arrest. These results establish a global hijacking mechanism for SS18-SSX on chromatin, and define the distinct contributions of two concurrent BAF complex perturbations.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available